METTL3 and skin basal cell carcinoma: Furthermore, we have further extended the functional relevance of this mechanism by showing that interfering METTL3 or DGCR8 or the small molecular inhibitor of METTL3, STM2457 alleviated the BCC-elicited DOXIC aggravating effects mediated by D-BCC-sEVs.